Peptide-based delivery of agents
AssigneeThe Florey Institute of Neuroscience and Mental Health
InventorsFazel SHABANPOOR, Bradley TURNER
Life of this patent
Estimating the term…
Abstract
Described herein are fusion peptides comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an endosomal escape domain. Such fusion peptides can be conjugated with an active agent to deliver the active agent across the blood-brain barrier to the central nervous system and across blood-ocular barriers to the eye.
Claims34
A fusion peptide comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an endosomal escape domain.
A fusion peptide comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1, a derivative thereof, or a sequence at least about 80% identical thereto and (ii) a peptide sequence comprising the amino acid sequence of SEQ ID NO:3, a derivative thereof, or a sequence at least about 80% identical thereto.
Use of a fusion peptide comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an endosomal escape domain, for the targeted delivery of an active agent to the central nervous system (CNS) across the blood-brain barrier.
Use of a fusion peptide comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an endosomal escape domain, for the targeted delivery of an active agent to the eye across a blood-ocular barrier.
Dependencies are inferred from the claim text.